Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA14 LOXIMED G Moxifloxacin (HCl) - 400mg 400mg Tablet 851,100 L.L
J01MA14 LOXIPHAR G Moxifloxacin (HCl) - 400mg 400mg Tablet 1,063,555 L.L
J01XX08 LINEZOLID ARROW G Linezolide - 600mg/300ml 2mg/ml Injectable solution 13,282,147 L.L
J01XX08 LINEDOR G Linezolide - 600mg/300ml 600mg/300ml Injectable solution 2,045,328 L.L
J01XX08 LINESPAN 600 G Linezolide - 600mg 600mg Tablet, film coated 3,308,540 L.L
J01XX08 LINEZOLIDE STRAGEN G Linezolide - 600mg 600mg Tablet, coated 5,848,403 L.L
J05AB01 LOVRAK-JULPHAR G Aciclovir - 250mg 250mg Injectable lyophilised powder 278,175 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 150mg 150mg Tablet, coated, scored 7,850,907 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 300mg 300mg Tablet, coated 7,850,907 L.L
J05AR01 LAMIVUDINE/ ZIDOVUDINE ARROW G Lamivudine - 150mg, Zidovudine - 300mg Tablet, coated, scored 15,643,319 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
L01BB04 LITAK 10 B Cladribine - 2mg/ml 2mg/ml Injectable solution 114,341,349 L.L
L01BB04 LITAK 10 B Cladribine - 10mg/5ml 10mg/5ml Injectable solution 39,016,157 L.L
L01BC59 LONSURF B Trifluridine - 20mg, Tipiracil - 8.19mg Tablet, film coated 75,019,126 L.L
L01BC59 LONSURF B Trifluridine - 15mg, Tipiracil - 6.14mg Tablet, film coated 58,102,683 L.L
L01ED05 LORBRENA B Lorlatinib - 25mg 25mg Tablet 134,559,469 L.L
L01ED05 LORBRENA B Lorlatinib - 100mg 100mg Tablet 403,677,371 L.L
L01EX08 LENVIMA B Lenvatinib - 4mg 4mg Capsule, hard 120,133,345 L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard 120,133,345 L.L
L01XK01 LYNPARZA B Olaparib - 100mg 100mg Tablet, film coated 230,789,350 L.L
L01XK01 LYNPARZA B Olaparib - 150mg 150mg Tablet, film coated 230,789,350 L.L
L02BG04 LEFFTARA G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,060,111 L.L
L02BG04 LETROZOLE ARROW G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,402,790 L.L
L02BG04 LETROZOLE NEAPOLIS G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,060,111 L.L
L02BG04 LETROZOLE BIOGARAN G Letrozole - 2.5mg 2.5mg Tablet, coated 2,402,790 L.L
L02BG04 LETROZOLE ARROW LAB G Letrozole - 2.5mg 2.5mg Tablet, coated 2,000,981 L.L
L04AX04 LENOMA G Lenalidomide - 5mg 5mg Capsule, hard 68,908,116 L.L
L04AX04 LENALIDOMIDE OHRE PHARMA G Lenalidomide - 5mg 5mg Capsule 30,336,491 L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 5mg 5mg Capsule 68,908,116 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 5mg 5mg Capsule, hard 71,647,217 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025